Cresco Labs Inc (CRLBF) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Cresco Labs Inc $1.90, price $0.67, upside +183.6%, quality 31 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Cresco Labs Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 1, 2026.
How to read this chart
60‑month range $0.4320 – $11.59 · fair‑value band $0.6600 – $3.58 · the $0.6700 price screens below the $1.90 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Oct 1, 2026.
Follow Cresco Labs in your weekly email
Every Wednesday you see whether Cresco Labs is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Cresco Labs Inc. cultivates, manufactures, and sells retail and medical cannabis products in the United States and Germany.
Show more
Cresco Labs Inc. cultivates, manufactures, and sells retail and medical cannabis products in the United States and Germany. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes, gummies, and pre-rolls under the Good News brand; vapes and edibles under the Wonder Wellness Co. brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand. The company offers cannabis flowers under the FloraCal brand; and cannabis oils and variety of bites are available at multiple potency levels under the Mindy's brand, as well as Loud*r brand. In addition, the company offers cannabis-infused edibles under the Sunnyside brand. The company is headquartered in Chicago, Illinois.
Stock analysis
Cresco Labs Inc (CRLBF) currently trades at $0.6700, while our model-based Fair Value estimate is $1.90, implying the stock looks roughly 64.7% undervalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of $2.68 per share, and 10 of the 11 models we run sit above the $0.6700 price.
Bear case: the Asset-Based group reads lowest at $0.4800, and 1 of the 11 models stay below the price. Evidence for this calculation is low.
Scenario range: $0.6600 (bear) to $3.58 (bull), the price of $0.6700 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 31/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Cresco Labs Inc reported revenue of $656M in FY2025 versus $822M in FY2021, a compound −5.5%/yr. Reported net income was −$135M in FY2025.
Key figures
Market cap $241M · P/S ratio 0.36 · EPS (TTM) $−0.3200 · Net margin −20.6% · Return on equity −36.1% · Return on assets (EBIT) 5.5% · Operating margin 7.7% · Revenue (TTM) $651M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 29 out of 100 (medium confidence).
What moves the price
The share trades about 65% below its 52-week high and 6% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at 184%, CRLBF screens cheaper than that median.
Fair Value models
Bear $0.6600Fair Value $1.90Bull $3.58
Price $0.6700 · Upside +183.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.28/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−9.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−8.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.6%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+47.5%
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−26.7% (2019) → 15.1% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+18.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+3.2%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +16.1% a year for the price and +0.8% for the forecasts.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 593 stocks
Beats the industry median on 6/10 measures
Overall it ranks above its industry peers.
Valuation
Quality Score31 · Bottom 25%
Fair Value upside+183.6% · Top 25%
Profitability
Return on assets3.0% · Above median
Net margin (TTM)−15.5% · Bottom 25%
Operating margin (TTM)7.7% · Below median
Growth and dividend
Revenue growth5.9% · Above median
Balance sheet
Debt / equity1.65× · Highest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/B0.95× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Cresco Labs Inc (CRLBF) overvalued or undervalued?
As of Oct 1, 2026, our model estimates a fair value of $1.90 versus a price of $0.6700, about +184% upside (undervalued).
What is the fair value of CRLBF?
Our model-based fair value for Cresco Labs Inc is $1.90 (as of Oct 1, 2026), built from audited fundamentals. The current price: $0.6700.
What is the quality score of CRLBF?
Cresco Labs Inc has a Quality Score of 31/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Cresco Labs Inc (CRLBF)?
Our model-based price target is the fair value of $1.90 (as of Oct 1, 2026) from 11 valuation models. Cautious scenario $0.6600, optimistic scenario $3.58. It is a calculation from audited fundamentals, not an analyst target.
What is the Cresco Labs Inc stock forecast for 2026?
Our models put fair value at $1.90, about +184% upside versus a price of $0.6700 (undervalued). Cautious scenario $0.6600, optimistic scenario $3.58. The calculation is refreshed regularly with new filings.
What is the revenue of Cresco Labs Inc (CRLBF)?
Cresco Labs Inc reported trailing-twelve-month revenue of about $651M (latest available figure, as of Oct 1, 2026).
What growth is priced into Cresco Labs Inc (CRLBF)?
For today's price to be fair in a discounted-cash-flow model, Cresco Labs Inc would have to grow free cash flow by +18.8 % per year for five years (discount rate 15.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +6.6 % per year. As of Oct 1, 2026.
What discount rate (WACC) does the fair value of CRLBF use?
Our models discount Cresco Labs Inc at 15.2 %: a base by market capitalisation (micro), damped by beta 1.77, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Cresco Labs Inc that is +18.8 % per year a year over ten years, using the same discount rate (15.2 %) and the same formula as our fair value.
How much growth has Cresco Labs Inc (CRLBF) delivered so far?
Over the past 5 years revenue at Cresco Labs Inc grew +6.6 % a year. The price currently implies +18.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Cresco Labs Inc (CRLBF) growing?
The median revenue growth in the sector is +5.2 % a year. That is the yardstick for the growth priced into Cresco Labs Inc (+18.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Cresco Labs Inc (CRLBF)?
The free-cash-flow yield on the price is 14.41 %: that much free cash flow Cresco Labs Inc produces per unit of market value. When it exceeds the discount rate of our models (15.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Cresco Labs Inc (CRLBF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Cresco Labs Inc it is $1.90 per share (as of Oct 1, 2026), against a price of $0.6700. It is the blended result of 11 valuation models (cash flow, earnings, asset, dividend).
Is Cresco Labs Inc stock overvalued or undervalued in 2026?
As of Oct 1, 2026, CRLBF trades below its calculated fair value: price $0.6700, fair value $1.90, a gap of about +184% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CRLBF?
No. The price is what the market pays today ($0.6700); the fair value is what the company's own numbers justify ($1.90). For Cresco Labs Inc the two are $1.23 per share apart. That gap is exactly why we show both numbers side by side.
How much is Cresco Labs Inc worth?
The market values Cresco Labs Inc at about $241M (market capitalisation, as of Oct 1, 2026). Per share that is $0.6700; our models calculate a fair value of $1.90 per share.
What do the bullish and bearish scenarios say about CRLBF?
Our models span a range for Cresco Labs Inc: cautious scenario $0.6600, base $1.90, optimistic $3.58 per share (as of Oct 1, 2026, price $0.6700). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Cresco Labs Inc (CRLBF)?
Balance-sheet figures for Cresco Labs Inc (as of Oct 1, 2026): return on equity −36.1%, debt of 1.65 per unit of equity. They feed the Quality Score of 31/100, which measures business quality independently of the share price.
How far is CRLBF from its 52-week high?
Cresco Labs Inc trades at $0.6700, about 65% below its 52-week high of $1.92 and 6% above the low of $0.6350 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $1.90 is for.
Which stocks are comparable to Cresco Labs Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Cresco Labs Inc stock attractive at the current price?
The data as of Oct 1, 2026: price $0.6700, calculated fair value $1.90 (+184%), Quality Score 31/100, from 11 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CRLBF calculated?
We run Cresco Labs Inc through 11 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $1.90, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. Cresco Labs Inc currently trades 65 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Cresco Labs Inc (CRLBF)?
The closing price on Oct 2, 2026 was $0.6700. Our model-based fair value is $1.90, about +184% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Cresco Labs Inc right now?
The large discount to fair value meets weak quality (31/100). That raises the risk this is a value trap rather than a bargain. The model range is unusually wide ($0.6600 to $3.58). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Cresco Labs Inc
How large is the market capitalisation of Cresco Labs Inc (CRLBF)?
The market capitalisation of Cresco Labs Inc is $241M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Cresco Labs Inc (CRLBF)?
The price-to-sales ratio of Cresco Labs Inc is 0.36 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Cresco Labs Inc (CRLBF)?
Earnings per share at Cresco Labs Inc are $−0.3200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Cresco Labs Inc (CRLBF)?
The net margin of Cresco Labs Inc is −20.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Cresco Labs Inc (CRLBF)?
The return on equity (ROE) of Cresco Labs Inc is −36.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Cresco Labs Inc (CRLBF)?
On an EBIT basis the return on assets of Cresco Labs Inc is 5.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Cresco Labs Inc (CRLBF)?
The operating margin of Cresco Labs Inc is 7.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Cresco Labs Inc (CRLBF)?
Revenue at Cresco Labs Inc is growing +5.9% versus a year earlier (3y avg −8.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Cresco Labs Inc (CRLBF)?
Earnings per share at Cresco Labs Inc are growing −83.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Cresco Labs Inc (CRLBF) carry?
The net debt of Cresco Labs Inc is $367M (fiscal year 2025, ≈ 10.6 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Cresco Labs Inc in the live analysis
One click puts Cresco Labs Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Oct 1, 2026